Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)

References

• Ding J, Miao ZH, Meng LH, Geng MY. Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol Sci 2006;27:338–44.
   PubMed Web of Science ®Google Scholar
• Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012;13:411–24.
   PubMed Web of Science ®Google Scholar
• D’amours D, Desnoyers S, D’silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in there gulation of nuclear functions. Biochem J 1999;342: 249–68.
   PubMed Web of Science ®Google Scholar
• Morales JC, Li LS, Fattah FJ, et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr 2014;24:15–28.
   PubMed Web of Science ®Google Scholar
• Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair 2004;3:1103–8.
   PubMed Web of Science ®Google Scholar
• Gao CZ, Dong W, Cui ZW, et al. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors. J Enzyme Inhib Med Chem 2019;34:150–62.
   PubMed Web of Science ®Google Scholar
• Wang ZQ, Auer B, Stingl L, et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 1995;9:509–20.
   PubMed Web of Science ®Google Scholar
• Wang YQ, Wang PY, Wang YT, et al. An update on Poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy. J Med Chem 2016;59:9575–98.
   PubMed Web of Science ®Google Scholar
• Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem 2010;53:4561–84.
   PubMed Web of Science ®Google Scholar
• Vyas S, Chang P. New PARP targets for cancer therapy. Nat Rev Cancer 2014;14:502–9.
   PubMed Web of Science ®Google Scholar
• He JX, Yang CH, Miao ZH. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol Sin 2010;31:1172–80.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205–14.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014;32:3840–7.
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008;51:6581–91.
   PubMed Web of Science ®Google Scholar
• Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6:945–56.
   PubMed Web of Science ®Google Scholar
• Jones P, Wilcoxen K, Rowley M, Toniatti C. Niraparib: a Poly(ADP-ribose) Polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem 2015;58:3302–14.
   PubMed Web of Science ®Google Scholar
• Zhou JX, Feng LJ, Zhang X. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2017;11:3009–17.
   PubMed Web of Science ®Google Scholar
• Liu Y, Meng J, Wang G. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Des Devel Ther 2018;Volume 12:3013–9.
   Web of Science ®Google Scholar
• Toure M, Crews CM. Small-molecule PROTACS: new approaches to protein degradation. Angew Chem Int Ed Engl 2016;55:1966–73.
   PubMed Web of Science ®Google Scholar
• Ottis P, Crews CM. Proteolysis-targeting chimeras: induced protein degradation as a therapeutic strategy. ACS Chem Biol 2017;12:892–8.
   PubMed Web of Science ®Google Scholar
• Churcher I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? J Med Chem 2018;61:444–52.
   PubMed Web of Science ®Google Scholar
• Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov 2017;16:101–14.
   PubMed Web of Science ®Google Scholar
• Xi M, Chen Y, Yang H, et al. Small molecule PROTACs in targeted therapy: an emerging strategy to induce protein degradation. Eur J Med Chem 2019;174:159–80.
   PubMed Web of Science ®Google Scholar
• Zhang C, Han XR, Yang X, et al. Proteolysis targeting chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). Eur J Med Chem 2018;151:304–14.
   PubMed Web of Science ®Google Scholar
• Lu M, Liu T, Jiao Q, et al. Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway. Eur J Med Chem 2018;146:251–9.
   PubMed Web of Science ®Google Scholar
• Wang B, Wu S, Liu J, et al. Development of selective small molecule MDM2 degraders based on nutlin. Eur J Med Chem 2019;176:476–91.
   PubMed Web of Science ®Google Scholar
• Li W, Gao C, Zhao L, et al. Phthalimide conjugations for the degradation of oncogenic PI3K. Eur J Med Chem 2018;151:237–47.
   PubMed Web of Science ®Google Scholar
• Han X, Wang C, Qin C, et al. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem 2019;62:941–64.
   PubMed Web of Science ®Google Scholar
• Hu J, Hu B, Wang M, et al. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). J Med Chem 2019;62:1420–42.
   PubMed Web of Science ®Google Scholar
• Qin C, Hu Y, Zhou B, et al. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) proteins capable of inducing complete and durable tumor regression. J Med Chem 2018;61:6685–704.
   PubMed Web of Science ®Google Scholar
• Schiedel M, Herp D, Hammelmann S, et al. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). J Med Chem 2018;61:482–91.
   PubMed Web of Science ®Google Scholar
• Edmondson SD, Yang B, Fallan C. Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: recent progress and future challenges. Bioorg Med Chem Lett 2019;29:1555–64.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Lan T, Su S, Rao Y. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. Chem Commun 2019;55:369–72.
   PubMed Web of Science ®Google Scholar
• Gadd MS, Testa A, Lucas X, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol 2017;13:514–21.
   PubMed Web of Science ®Google Scholar
• Webster R, Didier E, Harris P, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 2007;35:9–16.
   PubMed Web of Science ®Google Scholar
• Germain M, Affar EB, D’Amours D, et al. Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. evidence for involvement of caspase-7. J Biol Chem 1999;274:28379–84.
   PubMed Web of Science ®Google Scholar
• Guo C, Wang L, Li X, et al. Discovery of novel bromophenol-thiosemicarbazone hybrids as potent selective inhibitors of Poly(ADP-ribose) polymerase-1 (PARP-1) for use in cancer. J Med Chem 2019;62:3051–67.
   PubMed Web of Science ®Google Scholar